- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.08. | Forbion, OrbiMed-backed Sitala seals $670M deal for Fosun immune disease drug | ||
| 26.08. | Sanofi snags BioMarin leader to take on CMO role 8 months after Berger's exit | ||
| 26.08. | Regeneron reports key phase 3 win in myasthenia gravis, gears up for FDA filing | ||
| 26.08. | Novartis pens BioArctic pact worth $30M upfront to find new drug in neurodegeneration field | ||
| 26.08. | NCI axes funding for pediatric brain cancer trial consortium, shifts focus to broader oncology group | ||
| 25.08. | Akeso scores twice in pair of phase 3 trials, teeing up regulatory submission in China | ||
| 25.08. | After layoffs, a CNS biotech attempts to break IPO ice for phase 3 funding | ||
| 25.08. | After month-long delay, Coya Therapeutics receives FDA go-ahead for ph. 2 ALS trial | ||
| 25.08. | Arnatar unveils with $52M, dual-modality RNA platform and rare disease asset | ||
| 25.08. | AbbVie tunes in to Gilgamesh's story, inking $1.2B deal for psychedelic program | ||
| 25.08. | PDS reports 39 months overall survival in Keytruda combination head and neck cancer trial | ||
| 22.08. | Supreme Court greenlights $783M in NIH grant cuts tied to Trump's DEI crackdown | ||
| 22.08. | Arena BioWorks, 19 months after splashy launch, lays off 30% of its staff | ||
| 22.08. | NIA beams $49M to Lighthouse for bacteria-related Alzheimer's disease trial | ||
| 21.08. | Krystal discontinues melanoma trial after FDA's Replimune rebuff: Stat | ||
| 21.08. | FDA accelerates Stealth Bio's rare disease application with a decision slated for next month | ||
| 21.08. | Gilead's Kite sails into in vivo CAR-T space with $350M Interius buyout | ||
| 21.08. | Dynavax's shingles vaccine holds its own against GSK's Shingrix in early clinical test | ||
| 20.08. | After a 'complete standstill,' private biotech market reaches new normal, investor says | ||
| 20.08. | Rocket launches from FDA hold, but uncertainty about the biotech's cash runway looms | ||
| 20.08. | Xoma adds fading Mural Oncology to portfolio of struggling biotechs | ||
| 20.08. | Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble | ||
| 20.08. | Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial | ||
| 19.08. | FDA rejection derails PTC Therapeutics' rare disease hopeful | ||
| 19.08. | FDA pushes back PDUFA date for Regenxbio's Hunter syndrome gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .